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A B S T R A C T
Acute graft-versus-host disease (aGVHD) remains a cause of excessive morbidity and mortality after alloge-
neic hematopoietic stem cell transplantation (HSCT). Primary treatment consists of high-dose corticosteroids,
but a small group of patients develop steroid-refractory disease, and their prognosis is especially poor. There
is experimental evidence that coexisting inﬂammation aggravates aGVHD. Because C-reactive protein (CRP)
is a systemic inﬂammatory marker, we aimed to investigate whether plasma CRP concentrations at the di-
agnosis of aGVHD can predict the risk of failing ﬁrst-line therapy and developing steroid-refractory disease.
We retrospectively studied 461 patients who underwent HSCT between 2010 and 2015. aGVHD grade II-IV
was diagnosed in 148 patients (32%). CRP level and total white blood cell, lymphocyte, and neutrophil counts
were available for all patients at the time of aGVHD diagnosis. According to local protocol, patients with failed
response to high-dose steroid therapy (2 mg/kg) were treated with the TNF-α inhibitor inﬂiximab and cat-
egorized as having steroid-refractory disease. Of 148 patients with grade II-IV aGVHD, 28 (19%) developed
steroid-refractory disease. In these patients, plasma CRP concentration at diagnosis ranged between <1 and
253 mg/L. CRP levels were signiﬁcantly higher in patients who developed steroid-refractory disease com-
pared with those who responded to high-dose corticosteroid therapy (odds ratio, 1.50; 95% conﬁdence interval,
1.18-1.93; P = .001). This translated into signiﬁcantly increased transplantation-related mortality and de-
creased overall survival in the patients with high CRP levels. Total white blood cell, lymphocyte, and neutrophil
counts were not associated with steroid resistance in the patients with aGVHD. These results suggest that
CRP level at diagnosis is a valid predictor of the development of steroid-refractory disease in patients who
develop grade II-IV aGVHD after HSCT.
© 2017 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT)
is a potential cure for a variety of malignant and nonmalig-
nant diseases. However, the alloreactivity required for the
graft-versus-leukemia effect is closely associated with graft-
versus host disease (GVHD), which remains one of the main
causes of transplantation-related mortality (TRM) after HSCT
[1,2]. Acute GVHD (aGVHD) is staged and graded according
to symptom severity in 3 main target organs: skin, liver,
and the gastrointestinal tract [3,4], and ﬁrst-line treatment
remains high-dose corticosteroids, typically starting at 1 to
2mg/kg/day [5]. Unfortunately, up to 50% of patients respond
inadequately to this treatment, resulting in a high mortali-
ty rate, and there is no consensus about the optimal second-
and third-line treatments [6,7].
Althoughmany risk factors for the development of aGVHD
have been identiﬁed, less is known about risk factors pre-
dicting initial treatment failure and steroid-refractory disease
in patients with aGVHD. aGVHD grade at onset, organ in-
volvement, maximum aGVHD grade, and time to initial
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treatment response have shown some associationwith patient
outcomes and survival [7-9]. Because the severity of symp-
toms at aGVHD diagnosis does not always accurately deﬁne
risk, the search for prognostic biomarkers is ongoing [10]. De-
creased serum albumin level and lymphocytopenia at
diagnosis have been associated with initial treatment failure
and decreased survival in patients with aGVHD [11,12]. Fecal
biomarkers have similarly been shown to predict steroid re-
sponse in patients with gastrointestinal aGVHD [13]. There
is increasing evidence that coexisting inﬂammation not only
aggravates aGVHD, but also contributes to the initial patho-
genesis [14,15]. The underlying disease, together with the pre-
HSCT conditioning regimen, creates an environment of
inﬂammation and increased activation of antigen-presenting
cells in target organs. This leads to activation of alloreactive
donor T cells and further release of proinﬂammatory
cytokines, resulting in an ampliﬁed and self-perpetuating in-
ﬂammation cascade that causes tissue damage to target organs
[16]. Logically, many of the investigated biomarkers reﬂect
speciﬁc proinﬂammatory cytokines or pathways in this in-
ﬂammatory process [10,17,18].
The acute-phase protein C-reactive protein (CRP) is a
widely used systemic inﬂammatory marker produced by he-
patocytes downstream of IL-6 during an acute inﬂammatory
response [19]. CRP has previously been investigated in the
setting of HSCT [20-26]. It has been shown that patterns of
CRP levels early after transplantation may correlate with both
TRM [24] and relapse [22], and that pre-engraftment CRP level
may predict the occurrence of GVHD in HSCT recipients [20].
Others have reported no increases in plasma levels of IL-6
and CRP in the course of GVHD, however [23,25]. To our
knowledge, no previous studies have evaluated CRP levels at
the time of aGVHD diagnosis in relation to the initial treat-
ment response. The aim of the present study was to assess
whether the plasma CRP concentration at the onset of aGVHD
is predictive of steroid-refractory aGVHD and TRM in a ret-
rospective cohort of patients with grade II-IV aGVHD.
PATIENTS AND METHODS
Patients
A total of 511 patients underwent HSCT at the Bone Marrow Transplan-
tation Unit, Department of Hematology, Copenhagen University Hospital,
Rigshospitalet between January 2010 and December 2015. Patients under-
going transplantation with umbilical cord blood, treated with donor
lymphocyte infusions, or undergoing more than 1 transplantation were ex-
cluded, leaving 464 patients for evaluation. Three of these patients did not
have data on CRP level and differentiated WBC available for analysis at time
of aGVHD diagnosis. Patient and transplantation characteristics for the re-
maining 461 patients included in this study are presented in Table 1. The
median patient age was 53 years (range, 16-75 years), and the median du-
ration of follow-up was 1340 days (range, 311-2480 days). Signed informed
consent was obtained from each patient or a legal guardian allowing anal-
ysis of clinical and laboratory data for research in advance.
Donors and Stem Cell Sources
One hundred and ﬁfteen patients had an HLA-identical sibling donor,
and 1 patient had a 10/10 HLA allele-identical other related donor (mother).
Three hundred and seven patients had a 10/10 or 9/10 HLA allele-matched
unrelated donor, and 35 patients had an unrelated donor with an antigen
mismatch. Three patients had an unrelated donor with more than 1 antigen
mismatch. The stem cell sourcewas bonemarrow (BM) or granulocyte colony-
stimulating factor-stimulated unmanipulated peripheral blood stem cells
(PBSCs).
Conditioning Regimen
Myeloablative regimens were cyclophosphamide 120 mg/kg plus 12 Gy
of total body irradiation (TBI) or busulfan (Busilvex) 12.2 mg/kg in myeloid
diseases; cyclophosphamide was replaced with etoposide phosphate
(Etophophos) 1800 mg/m2 in lymphoid diseases. Doses of cyclophospha-
mide and Busilvex were calculated using an adjusted ideal body weight in
patients with a body mass index >27.5. Nonmyeloablative conditioning was
provided with ﬂudarabine 90 mg/m2 plus 2 Gy TBI, increased to 4 Gy in pa-
tients not previously treated with chemotherapy. Patients with high-risk
myelodysplastic syndrome were conditioned with ﬂudarabine 150 mg/kg
plus treosulfan 42mg/kg. The conditioning regimen for patients with severe
aplastic anemia was cyclophosphamide 200 mg/kg plus 2 Gy TBI and
thymoglobulin 6.75 mg/kg in those with an unrelated donor.
GVHD Prophylaxis
Patients receivingmyeloablative conditioningwere given oral cyclosporine
6.25 mg/kg twice daily starting on day -1 combined with a short course of
i.v. methotrexate on days +1 (15 mg/m2), +3, +6, and +11 (10 mg/m2).
Cyclosporine was tapered to stop on day +180, unless GVHD was present.
Tacrolimus was administered to the patients receiving the ﬂudarabine/
treosulfan regimen. Patients receiving nonmyeloablative conditioning were
given oral tacrolimus .06 mg/kg twice daily starting on day -3 along with
mycophenolate mofetil 15 mg/kg twice daily from day 0 to day +27 in re-
cipients of a related donor transplant. In recipients of an unrelated transplant,
oral tacrolimus .06 mg/kg twice daily starting on day -3 was combined with
oral mycophenolate mofetil 15 mg/kg three times daily from day 0 to day
+30, twice daily to day +40, and then tapered to stop on day +96 in the
absence of GVHD. In the absence of GVHD, tacrolimus was tapered start-
ing on day +56 to zero by day +180 in recipients of related nonmyeloablative
Table 1
Patient and Transplantation Characteristics
Characteristic Value
Patients, n 461
Follow-up time, d, median, range 1340 (311-2480)
Age, yr, median, range 53 (16-75)
Disease, n
Acute myelogenous leukemia 173
Myelodysplastic syndrome 111
Acute lymphoblastic leukemia 58
Non-Hodgkin lymphoma 37
Chronic lymphocytic leukemia 27
Chronic myelogenous leukemia 18
Severe aplastic anemia 15
Other 22
Risk score*, n
Early 262
Intermediate 184
Late 15
Donor type, n
Sibling 115
Other matched related 1
Matched unrelated 307
Mismatched unrelated 38
Patient-donor sex match, n
Female-female 100
Female-male 71
Male-male 202
Male-female 88
Stem cell source, n
Bone marrow 118
PBSCs 343
Conditioning regimen, n
Myeloablative 201
Reduced intensity 7
Nonmyeloablative 253
Conditioning regimen, n
Cyclophosphamide-TBI 87
Cyclophosphamide-busulfan 15
Etophophos-TBI 49
Fludarabine-TBI 250
Fludarabine-treosulfan 32
Cyclophosphamide-ATG +/- TBI 15
Other 13
aGVHD, n 204
aGVHD grade I, n 56
aGVHD grade II, n 102
aGVHD grade III, n 34
aGVHD grade IV, n 12
Chronic GVHD, n 227
* Risk score from the European Group for Blood and Marrow Transplan-
tation.
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transplants, and from day +100 to zero by day +180 in recipients of unre-
lated nonmyeloablative transplants.
GVHD Diagnosis and Treatment
aGVHD and chronic GVHD were diagnosed and graded based on clini-
cal symptoms and biopsy analysis according to the modiﬁed Glucksberg-
Seattle criteria [3,4]. aGVHD grade II-IV was treated withmethylprednisolone
2 mg/kg. Patients showing disease progress within 3 days or inadequate
response (ie, no response) within 1 week on this treatment were started on
second-line treatment consisting of TNF-α antibody (inﬂiximab 10 mg/kg)
and occasionally extracorporeal photopheresis (ECP). Patients treated with
inﬂiximabwere categorized as having steroid-refractory disease in this study.
Chronic GVHD was treated with prednisolone 1 mg/kg, supplemented with
calcineurin inhibitors, mycophenolate mofetil, sirolimus, or ECP at the dis-
cretion of the treating physician.
Overall Survival and Transplant Related Mortality
Overall survival (OS) was deﬁned as the probability of survival from the
time of HSCT to time of death or last follow-up. Surviving patients were cen-
sored at last follow-up, and only death was considered an event. TRM was
deﬁned as death from causes other than relapse.
Laboratory Samples
In our institution, plasma CRP concentrations, together with differen-
tiated WBC, are measured routinely after HSCT and consistently in patients
under observation for the development of aGVHD. CRP concentration in
plasmawasmeasured using the CRPL3 turbidimetric assay (Modular P chem-
istry analyzer; Hitachi, Tokyo, Japan) (normal range, 0-10mg/L). In this study,
all patients had a CRP/WBC measurement on the day of aGVHD diagnosis
or 1 day before.
Statistical Analyses and Endpoints
The primary aim of this study was to evaluate CRP levels at the time of
aGVHD diagnosis in patients with aGVHD grade II-IV in correlation with the
development of steroid-refractory disease and subsequent TRM and OS. Sec-
ondary aims were to evaluate WBC and subgroups for the same outcomes.
Logistic regression with log-transformed continuous variables was used to
assess correlation. Differences between categorical and continuous vari-
ables were determined by the χ2 test and Student’s t test, respectively.
Differences among groupmeans (more than 2 groups) were analyzed by one-
way analysis of variance. Estimated OSwas determined by univariate analysis
using the Kaplan-Meier method and the log-rank test. Cumulative inci-
dence rates of TRM, GVHD, and relapsewith competing events were compared
using Gray’s test. All P values were 2-sided and considered statistically sig-
niﬁcant at <.05. CRP level in relation to the occurrence of steroid-refractory
aGVHD was analyzed as a continuous variable in logistic regression and as
a dichotomized, categorical variable in survival and cumulative incidence
analyses. In the logistic regression analysis, the log2 transformation of CRP
level was performed to ﬁt the statistical model for logistic regression. Thus,
interpretation of the odds ratio (OR) is the estimated increase in probabil-
ity of developing steroid-refractory aGVHD by each doubling of any arbitrary
CRP level. CRP was used as a continuous variable in logistic regression anal-
ysis to obtain a statistically robust and direct correlationwith the development
of steroid-refractory disease. In the Kaplan-Meier analysis for OS and the
Gray’s test for cumulative incidence, CRP levels were dichotomized at the
normal cutoff of 10 mg/L. Statistical analyses were performed using SPSS
version 22 (SPSS, Chicago, IL), SAS Enterprise Guide 7.1 (SAS Institute, Cary,
NC), and R version 3.2.0 (R Foundation for Statistical Computing, Vienna,
Austria) combined with the EZR platform [27].
RESULTS
Among the 461 patients, 300 (65%) were alive after a
median follow-up of 1340 days (range, 311-2480 days).
Seventy-four patients (16%) died from relapse, and 87 (19%)
died from TRM. aGVHDwas diagnosed in 203 patients (44%),
and 227 patients (49%) experienced some degree of chronic
GVHD during the observation period (Table 1).
aGVHD Grade II-IV
A total of 148 patients (32%) developed grade II-IV aGVHD,
28 (19%) of whom developed steroid-refractory disease. No
patients with initial grade I aGVHD developed steroid-
refractory disease. Table 2 shows associations between
baseline factors and the development of grade II-IV aGVHD
and steroid-refractory aGVHD in all 461 patients. Age and graft
source showed statistically signiﬁcant associations with the
occurrence of grade II-IV aGVHD, and the use of high-
intensity TBI (12 Gy) was highly signiﬁcantly associated with
the development of grade II-IV aGVHD. In multivariate anal-
ysis including all of the factors listed in Table 2, only the use
of high-intensity TBI showed a statistically signiﬁcant asso-
ciation with the development of grade II-IV aGVHD (data not
shown). None of the factors investigated showed a statisti-
cally signiﬁcant association with the development of steroid-
refractory aGVHD, although there was a tendency toward an
association between high-intensity TBI and an increased in-
cidence of steroid-refractory disease in the univariate analyses
(Table 2).
The distribution of grade and organ involvement in the
148 patients grade II-IV aGVHD patients is shown in Table 3.
Of the 28 patients who developed steroid- refractory disease,
Table 2
Baseline Characteristics and Univariate Association with the Development of aGVHD Grade II-IV and Steroid-Refractory aGVHD in All Patients (n = 461)
Characteristic Patients, n aGVHD Grade II-IV Steroid-Refractory aGVHD
n (%) OR (95% CI) P Value n (%) OR (95% CI) P Value
Age, yr .59
≤53 237 86 (36) Reference .05 13 (5.5) Reference
>53 (median) 224 62(28) .67 (.45-1.00) 15 (6.7) 1.24 (.58-2.66)
Conditioning regimen .48
Myeloablative 201 80 (40) Reference .02 14 (7.0) Reference
Nonmyeloablative 260 68 (26) .54 (.36-.80) 14 (5.4) .76 (.35-1.63)
TBI .12
12 Gy 137 67 (49) Reference <.00 12 (8.8) Reference
Other 324 81 (25) .35 (.23-.53) 1 16 (4.9) .54 (.25-1.18)
Donor .67
Sibling 116 32 (28) Reference .23 8 (6.9) Reference
Matched unrelated 345 116 (34) 1.33 (.84-2.12) 20 (5.8) .83 (.36-1.94)
Donor/patient sex .87
Female/male 71 25 (35) Reference .54 4 (5.6) Reference
Other 390 123 (32) .85 (.50-1.44) 24(6.2) 1.10 (.37-3.27)
Allogeneic match .36
9/10 or 10/10 allele match 422 136 (32) Reference .85 27 (6.4) Reference
Other 39 12 (31) .94 (.46-1.90) 1 (2.6) .39 (.05-2.91)
Graft source .94
Bone marrow 118 47 (40) Reference .04 7 (5.9) Reference
PBSCs 343 101 (29) .63 (.41-.98) 21 (6.1) 1.03 (-43-2.50)
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22 (79%) died from TRM, at a median of 33 days (range, 8-384
days) from the ﬁrst inﬂiximab infusion. aGVHDwas the direct
cause of death in 16 of these patients, whereas the other 6
patients died from infection or organ failure.
CRP Levels and Steroid-Refractory Disease, TRM, and OS in
Patients with Grade II-IV aGVHD
Due to the inclusion criteria, laboratory results, includ-
ing CRP levels, were available for all patients with grade II-
IV aGVHD at the time of diagnosis or the day before. CRP levels
at diagnosis were between <1 and 253 mg/L (median, 17 mg/
L). CRP levels at diagnosis were signiﬁcantly higher in patients
who developed steroid-refractory disease compared with
those who responded to high-dose corticosteroids (OR, 1.50;
95% CI, 1.18-1.93; P = .001). Because CRP was analyzed as a
log2-transformed, continuous variable in the logistic regres-
sion analysis, the OR of 1.50 is interpreted as a 50% increase
in the estimated probability of developing steroid-resistant
disease by each doubling of any arbitrary CRP level. Pa-
tients with grade II-IV aGVHD with high CRP levels at
diagnosis had signiﬁcantly increased TRM compared with
those with lower CRP levels: Figure 1 shows this associa-
tion by patients divided into 2 groups by normal/elevated
(>10 mg/L) CRP, with 56 patients in the ≤10 mg/L group and
92 patients in the >10mg/L group. The increase in TRM trans-
lated into a signiﬁcantly lower OS in these patients (Figure 2).
Steroid-Refractory aGVHD and Other Factors
Table 4 lists baseline factors and possible risk factors at
diagnosis evaluated for associations with the development
of steroid-refractory aGVHD exclusively in patients with grade
II-IV aGVHD. None of the analyzed baseline factors or the time
to aGVHD onset showed a signiﬁcant association with the de-
velopment of steroid-refractory disease; however, grade at
onset (II versus III, given that no patients presentedwith grade
IV at diagnosis) and visceral involvement showed highly sig-
niﬁcant associations with increased risk of steroid-refractory
aGVHD. To evaluate whether CRP levels were predictive of
the development of steroid-refractory disease independent
of aGVHD grade at diagnosis and visceral involvement, we
performed a multivariate analysis with CRP (a log2-
transformed continuous variable), grade at diagnosis (II versus
III) and visceral involvement (yes versus no) in the 148 pa-
tients with grade II-IV aGVHD (Table 5). Although aGVHD
grade at diagnosis remained highly statistically signiﬁcant (P
< .0001), CRP level now failed to reach statistical signiﬁ-
cance (P = .16), and visceral involvement showed no tendency
Table 3
Disease Characteristics in Patients Developing Grade II-IV aGVHD (n = 148)
Characteristic Value
Time to aGVHD diagnosis, d, median (range) 34 (8-132)
Grade at diagnosis, n
Grade II 108
Grade III 40
Maximum grade, n
Grade II 102
Grade III 34
Grade IV 12
Organ involvement, n
Skin 88
Skin + gut 23
Skin + liver 5
Gut 28
Gut + liver 2
Liver 2
Veriﬁed involvement of multiple organs, n 30
Visceral involvement, n 62
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Figure 1. Cumulative incidence of TRM with death from relapse as competing event by CRP levels at diagnosis above and below 10 mg/L in patients with
grade II-IV aGVHD, n = 148.
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P = 0.01
Figure 2. Kaplan Meier estimate of OS by CRP levels >10 mg/L and <10 mg/L at diagnosis in patients with grade II-IV aGVHD (n = 148).
Table 4
Possible Risk Factors Associated with the Development of Steroid-Refractory Disease in Patients with Grade II-IV aGVHD at Baseline and at Diagnosis (n = 148)
Characteristic Patients, n Steroid-Refractory, n (%) OR (95% CI) P Value
Baseline
Age, yr .27
<49 72 11 (15) .63 (.27-1.45)
>49 (median) 76 17 (22) Reference
Conditioning regimen .63
Myeloablative 80 14 (18) Reference
Nonmyeloablative 68 14 (21) 1.22 (.53-2.79)
TBI .78
12 Gy 67 12 (18) Reference
Other 81 16 (20) 1.13 (.49-2.59)
Donor .32
Sibling 32 8 (25) 1.60 (.63-4.07)
Matched unrelated 116 20 (17) Reference
Donor/patient sex .68
Female/male 25 4 (16) Reference
Other 123 24 (20) 1.27 (.40-4.05)
Allogeneic match .35
9/10 or 10/10 allele match 109 27 (25) 2.7 (.34-22.03)
Other 11 1 (9) Reference
Graft source .40
Bone marrow 47 7 (15) .67 (.26-1.7)
PBSCs 101 21 (21) Reference
At aGVHD diagnosis
Days from HSCT to aGVHD, d .78
<30 67 12 (18) .89 (.39-2.03)
>30 81 16 (20) Reference
aGVHD grade at diagnosis <.001
II 108 6 (6) .05 (.02-.14)
III 40 22 (55) Reference
Visceral involvement in aGVHD .001
Yes 56 19 (34) Reference
No 92 9 (10) .21 (.09-.51)
CRP level at diagnosis, g/mL .05
<10 56 6 (11) .38 (.14-1.0)
>10 92 22 (24) Reference
Log2 CRP, continuous variable 1.50 (1.18-1.93) .001
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toward any statistical association (P = .94). Because there was
still a tendency toward a higher incidence of steroid-refractory
disease with increasing CRP levels, we analyzed grade II and
grade III aGVHD separately in multivariate analyses togeth-
er with visceral involvement (Table 5). In patients with grade
II aGVHD (n = 108), CRP level was associated with an in-
creased risk of steroid-refractory disease (P = .02), whereas
this association was not found in those with grade III aGVHD
(n = 40) (P = .89). Visceral involvement was not associatedwith
steroid-refractory disease in any group.
Total WBC, lymphocyte, and neutrophil counts were ana-
lyzed as continuous variables, and no association with the
development of steroid-refractory aGVHD was found (data
not shown).
CRP Levels and Steroid-Refractory aGVHD in Different
Organ Systems
The mean CRP levels at diagnosis for liver, gastrointesti-
nal, and skin aGVHD were 104 mg/L (range, 9-195 mg/L), 60
mg/L (range, 0-253 mg/L), and 36 mg/L (range, 0-223 mg/L),
respectively. One-way analysis of variance conﬁrmed a sta-
tistically signiﬁcant difference in mean values (data not
shown). We then analyzed skin aGVHD (n = 116) and gas-
trointestinal aGVHD (n = 53) separately in univariate and
multivariate analyses as described above, and found the same
results as for all patients with grade II-IV aGVHD. CRP level
at diagnosis was signiﬁcantly associated with an increased
risk of developing steroid-refractory disease in univariate anal-
ysis, but the association was no longer signiﬁcant in
multivariate analyses with aGVHD grade at diagnosis
included. The associations were similar for skin and gastro-
intestinal aGVHD, data not shown. Given that only 9 patients
had registered liver aGVHD at diagnosis, a separate analysis
was not performed for these patients.
DISCUSSION
In this study, we performed a retrospective analysis on the
potential for CRP level at diagnosis as a biomarker for the de-
velopment steroid-refractory aGVHD after HSCT. In our study
population of 461 patients who underwent HSCT for a variety
of malignant and nonmalignant diseases, the incidence of
steroid-refractory disease in patients with grade II-IV aGVHD
was 19%. Mortality was 79% in patients who did not respond
to high-dose steroid therapy. In patients with grade II-IV
aGVHD, increased CRP level at diagnosis predicted the de-
velopment of steroid-refractory disease. This ﬁnding is
consistent with the understanding of CRP as a marker of in-
ﬂammation. CRP is produced downstream of IL-6, which,
together with TNF-α and IFN-γ, are key players in the
proinﬂammatory cytokine cascade of aGVHD pathogenesis
[1,16]. Several preclinical and clinical studies have reported
the key role of IL-6 in driving GVHD [17,28,29]. Chen et al.
[28] found that blockade of IL-6 signaling attenuated the se-
verity of GVHD inmice, andMcDonald et al. [17] showed that
IL-6 level at the diagnosis of aGVHD predicted the develop-
ment of high-grade (III-IV) aGVHD in a prospective
multicohort study of patients with gastrointestinal aGVHD.
Other factors associated with an increased risk of steroid-
refractory disease in patients with grade II-IV aGVHD are high-
grade disease at diagnosis and visceral involvement. Other
studies have found associations with these clinical factors
[7,8]; however, recent studies have shown that algorithms con-
taining biomarkers strengthen the clinical prediction of failure
of ﬁrst-line treatment [10,18,30]. In our patient cohort, the
impact of aGVHD grade at diagnosis remained highly statis-
tically associated with steroid-refractory disease in the
multivariate analyses; however, the association with viscer-
al involvement disappears in multivariate analyses of all
patients with grade II-IV aGVHD and the separate analyses
of those with grade II and III at onset. CRP level lost statis-
tical signiﬁcance when aGVHD grade at diagnosis and visceral
involvement were included in the analysis of all patients with
grade II-IV aGVHD, making grade at diagnosis a highly potent
predictor of initial treatment response. However, the major-
ity (73%) of patients with grade II-IV aGVHD in our cohort
presented with grade II at diagnosis, and higher CRP level re-
mained signiﬁcantly associated with an increased risk of
steroid-refractory disease in a subgroup analysis of this patient
group (n = 108). The reason for the lack of any associationwith
steroid-refractory aGVHD in patients presenting with grade
III aGVHD at diagnosis might be the relatively low number
of patients (n = 40). In our cohort, patients with registered
liver aGVHD at diagnosis had signiﬁcantly higher CRP levels
comparedwith patients without liver involvement. This might
be consistent with the assumption that hepatic inﬂamma-
tion raises CRP, but should be veriﬁed in a larger patient
cohort. The statistically signiﬁcant association between CRP
level and steroid-refractory disease was similar in patients
with skin and gastrointestinal aGVHD analyzed separately,
and the association lost statistical signiﬁcance when aGVHD
grade at diagnosis was included in multivariate analyses. The
association between liver aGVHD and CRP level was not ana-
lyzed separately because of the low number of patients (n = 9).
Whether the possible predictive value of CRP level on the de-
velopment of steroid-refractory disease differs in different
organ systems with different initial grades merit investiga-
tion in future prospective studies with larger patient numbers.
CRP level was associated with an increased risk of steroid-
refractory disease in patients with grade II-IV aGVHD, and
because aGVHD is one of the major causes of TRM, we evalu-
ated the potential impact of CRP level at diagnosis on TRM
in the 148 patients with grade II-IV aGVHD. We found that
CRP level at diagnosis predicted an increased risk of death
from TRM, which translated into decreased OS. A major con-
founding factor could be the occurrence of infection at the
time of aGVHD diagnosis, with a possible impact of CRP levels.
A recent study conﬁrmed the mutual impact of aGVHD and
infections on each other, not only with the increased risk of
infections due to immunosuppression from aGVHD treat-
ment, but also with reported increased risk of infection before
the onset of aGVHD [31]. Unfortunately, data on infections
at the time of aGVHD diagnosis were limited in this retro-
spective study, and because we could not adjust for this factor,
the impact of concurrent infections on TRM cannot be
Table 5
Multivariate Analyses of Possible Risk Factors Associated with the Devel-
opment of Steroid-Refractory Disease in Patients with Grade II-IV and Grade
II and III Separately at Diagnosis of a GVHD
aGVHD Grade OR (95% CI) P value
II-IV (n = 148)
CRP 1.19 (.93-1.53) .16
Grade at aGVHD diagnosis .07 (.02-0.22) <.0001
Visceral involvement .96 (.29-3.17) .94
II (n = 108)
CRP 2.23 (1.16-4.25) .02
Visceral involvement .55 (.08-3.61) .55
III (n = 40)
CRP .98 (.72-1.33) .89
Visceral involvement 1.00 (.22-4.66) 1.00
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excluded. Therefore, TRM and OSwere analyzed only in a uni-
variate manner in this study, and so the main ﬁnding remains
the direct association between CRP level and the risk of
steroid-refractory aGVHD. Detailed data on possible infec-
tions together with parallel analyses of other inﬂammatory
markers, such as procalcitonin levels, may be useful in pro-
spective studies of the impact of CRP level in patients with
aGVHD [23]. Moreover, in this study, only the CRP level at the
time of aGVHD diagnosis was reported and analyzed in re-
lation to the development of steroid-refractory disease. In
prospective studies including information on the possible
competing inﬂuence of concurrent infections on CRP level,
the kinetics of CRP levels through the course of aGVHD treat-
ment might further elucidate the clinical value of CRP level
as a predictive marker of treatment response, together with
the initial level at diagnosis.
Several other factors, including conditioning regimen,
aplasia, mucositis and engraftment syndrome, could affect CRP
levels during the course of HSCT [26]. Conditioning regi-
mens have been shown to increase CRP levels to various
degrees, with antithymocyte globulin-containing regimens
the most inﬂuential [32,33]. These factors seem to affect CRP
levels primarily during the ﬁrst 1 to 2 weeks after HSCT, and
because the median time to diagnosis of grade II-IV aGVHD
in our patient cohort was 33 days, we believe that the impact
of these additional factors was less dominant. However,
further studies of CRP levels in a larger context at the time
of diagnosis of aGVHD are warranted to verify our ﬁndings.
Our univariate analyses of baseline risk factors and the oc-
currence of grade II-IV aGVHD in our patient cohort revealed
somewhat unexpected associations with young age and graft
source. The association between the use of bone marrow and
increased occurrence of grade II-IV aGVHD may be ex-
plained by the increased use of high- intensity TBI in patients
receiving this graft source; the loss of statistical signiﬁ-
cance between bone marrow and PBSCs in multivariate
analyses supports this idea. Surprisingly, we found no asso-
ciation between such otherwise known risk factors as
allogeneic mismatch, the use of unrelated donors, or in-
creased intensity of the conditioning regimen [34] in
univariate analyses. The strongest association with grade II-
IV aGVHD was with high-dose TBI as described previously
[34]. This supports the understanding, that local inﬂamma-
tion and endothelial tissue damage caused by irradiation is
an initial phase in the pathogenesis of aGVHD [1,16]. No sta-
tistical associations were observed between baseline factors
and the occurrence of steroid-refractory aGVHD in either the
patients with grade II-IV aGVHD or the entire patient cohort.
This may have been related to the low number of inci-
dences (28 in 461 patients), but also conﬁrms the need
for prognostic markers at the time of clinical aGVHD
manifestation.
In this study, steroid-refractory aGVHD was categorized
as treatment failure within 3 days or as inadequate re-
sponse to high-dose steroid treatment within 1 week. In
prospective studies, standardized treatment response as-
sessments at deﬁned time points may contribute to the
evaluation of the prognostic value of CRP level at diagnosis.
To demonstrate a direct and statistically robust correla-
tion between CRP level at aGVHD diagnosis and the
development of steroid-resistant disease, we included CRP
level as a continuous variable in the univariate and multi-
variate logistic regression analyses. In the survival analyses,
we chose to dichotomize CRP levels by the normal cutoff of
10mg/L, because more than one-third of patients with grade
II-IV aGVHD actually had a CRP level within the normal range
at diagnosis. Of course, alternative cutoffs or approaches could
be considered in future studies.
Contrary to other studies [11], we did not ﬁnd any asso-
ciation between lymphocyte count and the development of
steroid-refractory aGVHD; lymphocyte level was analyzed both
as a continuous variable as well as by previously described
cutoff of 100 cells/μL. Albumin is another standard serum
marker analyzed in the course of HSCT, which has been dem-
onstrated to be potentially prognostic for the development
of treatment failure in aGVHD [11,12]. Unfortunately, labo-
ratory albumin results were available in only a small portion
of our patient cohort and thus was not analyzed.
Other biomarkers identiﬁed as prognostic for the sever-
ity of aGVHD include ST2, TIM3, IL-6, TNFR1, and REG3α, all
of which are included in the regulation of inﬂammatory pro-
cesses in relation to tissue damage [10,17]. The 2015
multicenter study by Levine et al. [10] identiﬁed the vali-
dated plasma biomarkers ST2, TNF, and REG3α as valuable
in predicting 6-month nonrelapse mortality after the onset
of aGVHD independent of clinical grading systems, and sug-
gested a prognostic aGVHD score based on biomarkers. In
gastrointestinal aGVHD, the fecal biomarkers calprotectin and
alpha-1 antitrypsin have similarly been reported as predic-
tive of treatment response, along with grade at onset [13].
The role of CRP in the context of these speciﬁc plasma and/
or fecal biomarkers is not known, but because plasma CRP
analysis is a widely used and easy accessible test, a parallel
investigation of CRP in future studies on speciﬁc prognostic
biomarkers could be considered.
CONCLUSION
The poor outcomes in patients developing steroid-
refractory aGVHD in this study conﬁrms the need for improved
prognostic biomarkers for predicting the response to initial
treatment. We identiﬁed elevated CRP level at the time of
aGVHD diagnosis as signiﬁcantly associated with the devel-
opment of steroid-refractory disease in patients with grade
II-IV aGVHD. Closer monitoring with potentially earlier in-
terventions with second-line treatment in patients at
increased risk could improve treatment outcomes. Monitor-
ing of CRP levels along with clinical risk factors and additional
biomarkers of inﬂammation could be included in risk as-
sessment at the time of aGVHD diagnosis. Prospective studies
to further clarify the role of CRP level as a prognostic
biomarker of steroid-refractory aGVHD after HSCT are
warranted.
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